Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Chengdu Easton Biopharmaceuticals Co Ltd banner

Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513

Watchlist Manager
Chengdu Easton Biopharmaceuticals Co Ltd Logo
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Watchlist
Price: 47.55 CNY 6.49% Market Closed
Market Cap: ¥8.4B
Write Note Create Alert Ask AI

Wall St Price Targets

Price Targets Summary
Chengdu Easton Biopharmaceuticals Co Ltd

There are no price targets for Chengdu Easton Biopharmaceuticals Co Ltd.
Lowest Forecast
Wall Street Target
Not Available
Average Forecast
Wall Street Target
Not Available
Highest Forecast
Wall Street Target
Not Available
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Chengdu Easton Biopharmaceuticals Co Ltd Competitors:
Price Targets

Revenue
Forecast

8% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
8% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 7 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 3 years is 11%.

What are analyst estimates?

Gross Profit
Forecast

6% / Year
Past Growth
-1% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
6% / Year
Past Growth
-1% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 7 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 2 years is -1%.

What are analyst estimates?

Operating Income
Forecast

8% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss
8% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Over the last 7 years, the compound annual growth rate for Operating Income has been 8%. The projected CAGR for the next 3 years is 14%.

What are analyst estimates?

Pre-Tax Income
Forecast

11% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
11% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 7 years, the compound annual growth rate for Pre-Tax Income has been 11%. The projected CAGR for the next 3 years is 8%.

What are analyst estimates?

Net Income
Forecast

11% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
11% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 7 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 8%.

What are analyst estimates?

Continue Research

Summary
intrinsic value, competitors valuation, and company profile.
DCF Valuation
stock valuation using Discount Cash Flow valuation method.
Relative Valuation
stock valuation using valuation multiples.
Wall St Estimates
price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is Chengdu Easton Biopharmaceuticals Co Ltd's stock price target?
Not Available

Chengdu Easton Biopharmaceuticals Co Ltd does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Chengdu Easton Biopharmaceuticals Co Ltd?
Projected CAGR
11%

Over the last 7 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 3 years is 11%.

What is the Gross Profit forecast for Chengdu Easton Biopharmaceuticals Co Ltd?
Projected CAGR
-1%

Over the last 7 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 2 years is -1%.

What is the Operating Income forecast for Chengdu Easton Biopharmaceuticals Co Ltd?
Projected CAGR
14%

Over the last 7 years, the compound annual growth rate for Operating Income has been 8%. The projected CAGR for the next 3 years is 14%.

What is the Pre-Tax Income forecast for Chengdu Easton Biopharmaceuticals Co Ltd?
Projected CAGR
8%

Over the last 7 years, the compound annual growth rate for Pre-Tax Income has been 11%. The projected CAGR for the next 3 years is 8%.

What is the Net Income forecast for Chengdu Easton Biopharmaceuticals Co Ltd?
Projected CAGR
8%

Over the last 7 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 8%.

Back to Top
ALPHA SPREAD
Follow us
Join 357,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.